## **Core Concept**
The question tests understanding of the metabolic pathway of branched-chain amino acids (BCAAs) and the enzyme deficiency leading to a specific disorder. BCAAs (leucine, isoleucine, and valine) are metabolized through a series of reactions, one of which involves the enzyme **α-keto acid dehydrogenase** (also known as **α-keto acid decarboxylase**), a crucial step in their catabolism.

## **Why the Correct Answer is Right**
The correct answer, **Maple Syrup Urine Disease (MSUD)**, is a condition caused by a deficiency of the **branched-chain α-keto acid dehydrogenase complex** (BCKDC), also referred to as **α-keto acid decarboxylase** in the context of branched-chain amino acid metabolism. This enzyme complex is essential for the decarboxylation of α-keto acids derived from BCAAs. A deficiency leads to the accumulation of these amino acids and their toxic byproducts, resulting in severe neurological and metabolic symptoms. The name "Maple Syrup Urine Disease" comes from the distinctive sweet odor of the urine in affected patients.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Not provided, but presumably another metabolic disorder.
- **Option B:** Not provided, but presumably another condition.
- **Option C:** If this option suggests another disorder like **Hartnup disease** or **other aminoacidurias**, it's incorrect because these conditions involve different defects, such as transport issues rather than an enzymatic block in BCAA metabolism.
- **Option D:** Similarly, if suggesting a different metabolic defect, it would be incorrect for the same reason.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **Maple Syrup Urine Disease** presents early in life with symptoms like lethargy, poor feeding, and seizures, and if untreated, leads to severe intellectual disability and death. Early diagnosis through newborn screening and dietary restriction of BCAAs can significantly improve outcomes.

## **Correct Answer:** B. Maple Syrup Urine Disease.